MediciNova, Inc. 2022 Q2 Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. Its principal programs include MN-166 (ibudilast) for neurological, addiction and respiratory indications; MN-001 (tipelukast) for fibrotic diseases; MN-221 (bedoradrine); and MN-029 (denibulin).
The filing covers the quarter and six months ended June 30, 2022. The financial statements are unaudited and prepared under U.S. GAAP. MediciNova had 49,046,246 common shares outstanding as of August 9, 2022.
Financial Results and Key Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0.0 million in 2022; $0.0 million in 2021 | $0.0 million in 2022; $4.0 million in 2021 |
| Research, development and patents expense | $2.6 million; prior year $2.5 million | $4.7 million; prior year $4.7 million |
| General and administrative expense | $1.5 million; prior year $1.8 million | $2.8 million; prior year $3.8 million |
| Operating loss | $4.1 million; prior year $4.3 million | $7.5 million; prior year $4.5 million |
| Net loss | $4.0 million; prior year $4.3 million | $7.4 million; prior year $4.5 million |
| Net loss per share | $0.08 basic and diluted loss | $0.15 basic and diluted loss |
| Net cash used in operating activities | Not separately provided | $6.2 million; prior year $2.7 million |
Because the company reported no revenue in the quarter or year-to-date period, revenue-based margins are not meaningful. The six-month operating loss increased primarily because the prior-year period included $4.0 million of Genzyme milestone revenue.
Cash and cash equivalents were $65.2 million at June 30, 2022, compared with $71.4 million at December 31, 2021. Working capital was $62.1 million. Total assets were $81.2 million and total liabilities were $4.6 million. The filing does not disclose outstanding traditional debt; liabilities primarily comprise accounts payable, accrued liabilities, lease liabilities and other obligations. Total operating lease liabilities were $0.8 million.
Stockholders’ equity was $76.6 million at June 30, 2022, compared with $83.7 million at year-end 2021. The accumulated deficit was $400.5 million.
Material Changes Versus Prior Comparable Period
- Six-month revenue declined by $4.0 million to zero because the 2021 period included two Genzyme-related milestone payments.
- Six-month net loss increased to $7.4 million from $4.5 million, while six-month operating loss increased to $7.5 million from $4.5 million.
- Six-month operating cash burn increased by $3.5 million to $6.2 million.
- General and administrative expense declined by $1.0 million for the six months, primarily because of lower performance-based stock compensation.
- Research, development and patent expense was essentially unchanged for the six months, although MN-166 and MN-221 development costs increased and were offset by lower performance-based stock compensation.
- No shares were sold under the company’s $75.0 million 2019 at-the-market facility during the reported periods. Financing cash inflow was only $7,920 in the first six months of 2022, compared with $20.5 million in the prior-year period, which primarily reflected the 2021 private placement.
Cash Flow, Liquidity and Outlook
Cash declined by $6.2 million during the first six months of 2022, primarily due to operating cash use. Management stated that available working capital is expected to fund operations at least through the end of 2023, but cautioned that resources may not support all planned research and development programs. The company expects substantial net losses for the next several years.
Management expects research and development costs to increase through the remainder of 2022 as development programs progress. The company intends to pursue non-dilutive funding, grants, strategic alliances and pharmaceutical partnerships, but no specific financial guidance or commercialization timetable was provided.
Clinical, Regulatory and Other Risks
- MN-166 and MN-001 remain central to the development strategy, but successful clinical outcomes, regulatory approvals and commercialization are uncertain.
- The company announced top-line results in June 2022 for its completed MN-166 trial evaluating prevention of COVID-19-related acute respiratory distress syndrome; the filing does not provide the results or their financial implications.
- COVID-19 previously reduced patient visits at certain trial sites. Management reported improving visits and continued enrollment, while continuing to monitor effects on operations, suppliers, workforce and liquidity.
- The company depends on additional capital, potential partnerships, third-party clinical research organizations and manufacturers, and regulatory approvals.
- Future potential milestone payments under license agreements were estimated at $10.0 million for MN-166 and MN-001 and $33.5 million for other products. Timing is uncertain and no amounts were expended under these agreements during the reported periods.
- The Kissei collaboration agreement was being negotiated for termination, including cancellation of the remaining study; the company expected to finalize the termination agreement in 2022.
- No material legal proceedings were reported, and management stated that there were no material changes to previously disclosed risk factors.
Most Important Facts for Investors to Verify
- Whether the $65.2 million cash balance and stated runway through year-end 2023 remain adequate under the company’s current clinical development plans.
- Detailed top-line and subsequent clinical results for the MN-166 COVID-19 ARDS trial and other key programs.
- The status and terms of the expected Kissei agreement termination.
- The company’s ability to obtain grants, strategic partnerships or equity financing before cash resources decline materially.
- Future research and development spending, milestone obligations and potential dilution under the available ATM facility and outstanding options.